Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Whitehawk Therapeutics (WHWK) Gross Margin: 2018-2025

Historic Gross Margin for Whitehawk Therapeutics (WHWK) over the last 4 years, with Mar 2025 value amounting to 89.36%.

  • Whitehawk Therapeutics' Gross Margin rose 154.00% to 89.36% in Q1 2025 from the same period last year, while for Mar 2025 it was 88.72%, marking a year-over-year increase of 102.00%. This contributed to the annual value of 88.36% for FY2024, which is 10.00% down from last year.
  • According to the latest figures from Q1 2025, Whitehawk Therapeutics' Gross Margin is 89.36%, which was up 0.31% from 89.09% recorded in Q4 2024.
  • Whitehawk Therapeutics' 5-year Gross Margin high stood at 100.00% for Q1 2021, and its period low was 85.35% during Q4 2023.
  • Its 3-year average for Gross Margin is 88.51%, with a median of 88.85% in 2024.
  • Its Gross Margin has fluctuated over the past 5 years, first slumped by 1,397bps in 2022, then surged by 374bps in 2024.
  • Over the past 5 years, Whitehawk Therapeutics' Gross Margin (Quarterly) stood at 100.00% in 2021, then tumbled by 425bps to 95.75% in 2022, then crashed by 1,041bps to 85.35% in 2023, then skyrocketed by 374bps to 89.09% in 2024, then surged by 154bps to 89.36% in 2025.
  • Its last three reported values are 89.36% in Q1 2025, 89.09% for Q4 2024, and 88.85% during Q3 2024.